Hemex Health
Hemex Health develops the Gazelle point-of-care diagnostic platform, using microchip electrophoresis and AI-driven interpretation to detect sickle cell disease, beta thalassemia, and iron deficiency anemia in 8 minutes. It serves public health programs, ministries of health, and healthcare providers across more than 40 countries, with major supplier status for India's National Sickle Cell Anaemia Elimination Mission.
- Company typePrivate
- Founded2016
- HeadquartersPortland, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hemex Health does
Hemex Health, Inc. is a privately held medical diagnostics company founded in 2016 and headquartered in Portland, Oregon. The company develops the Gazelle diagnostic platform, a point-of-care system that detects and quantifies hemoglobin variants and biomarkers for sickle cell disease, beta thalassemia, and iron deficiency anemia. The platform combines miniaturized microchip electrophoresis and fluorescent immunoassay (FIA) technologies with AI-driven algorithms for automated result interpretation, delivering quantitative results in approximately 8 minutes from a small whole blood sample on a portable, battery-powered reader.
The company operates through a wholly-owned Indian subsidiary, HemexDx Pvt Ltd, which handles local manufacturing of Gazelle readers and consumables, engineering, customer service, and commercial operations in India. Revenue is generated through a hardware-plus-consumables model: sale or placement of Gazelle Readers plus recurring revenue from proprietary test consumables (Hb Variant multipacks and Ferritin FIA test strips). Distribution is primarily via a network of full-service medical distributors across more than 40 countries in Africa, the Middle East, South/Southeast Asia, and parts of Europe and Latin America, supplemented by direct engagement with public health ministries for large-scale screening programs.
Hemex's principal customer segments are public health programs, ministries of health, and healthcare providers in low-resource settings where laboratory infrastructure is limited. The company is a major supplier to India's National Sickle Cell Anaemia Elimination Mission, and has received an FDA Breakthrough Device Designation (February 2026) for the Gazelle Hb Variant Test for sickle cell disease monitoring. Strategic capital partners include Terumo Blood and Cell Technologies (corporate investment, October 2025) and MedAccess (working capital facility, September 2025), alongside grant funding from the NIH ($3M, March 2023) and CTIP. The product is not yet cleared for sale in the United States.
Hemex Health firmographics
Firmographics- Name
- Hemex Health
- Legal name
- Hemex Health Inc.
- Website
- https://hemexhealth.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Hemex Health develops the Gazelle point-of-care diagnostic platform, using microchip electrophoresis and AI-driven interpretation to detect sickle cell disease, beta thalassemia, and iron deficiency anemia in 8 minutes. It serves public health programs, ministries of health, and healthcare providers across more than 40 countries, with major supplier status for India's National Sickle Cell Anaemia Elimination Mission.
- Ownership category
- akta.pro rank
Hemex Health industry classification
Industry- Product category
- In-vitro diagnostic medical devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Hematology POCT (CBC/hemoglobin/hematocrit) (HLAHAOAD)
- akta.pro secondary industries
- Hematology & Coagulation Diagnostics (HLAHAAAB), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH)
Keywords
Where Hemex Health is headquartered
LocationHeadquarters
- HQ city
- Portland
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Hemex Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Gazelle Diagnostic Device (Reader): Sale of the Gazelle diagnostic device/reader to healthcare facilities and distributors.
- Gazelle Hb Variant Test Multipacks: Recurring revenue from consumable test kits (S-10B Multipack) used with the Gazelle reader for hemoglobin variant detection.
- Gazelle Ferritin FIA Test Strips: Recurring revenue from ferritin test strip consumables for iron deficiency anemia detection.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing through medical distributors |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels6 records
Hemex Health product offering
Product offeringCore offering
Hemex Health develops and sells the Gazelle diagnostic platform, a point-of-care system combining a portable reader device with proprietary microchip electrophoresis and fluorescent immunoassay (FIA) test cartridges to detect and quantify hemoglobin variants (sickle cell disease, beta thalassemia) and ferritin (iron deficiency anemia) in 8 minutes from a small whole blood sample, supported by AI-driven result interpretation and a cloud application for data management.
Product overview
Hemex Health offers the Gazelle diagnostic platform—a unified point-of-care system for detecting blood-based conditions. The platform consists of the Gazelle Reader hardware device, two primary test products (Gazelle Hb Variant Test using microchip electrophoresis and Gazelle Ferritin FIA Test using fluorescent immunoassay), and the Gazelle Cloud Application for data management. The platform integrates AI-driven algorithms for automated result interpretation and is designed for use in low-resource settings with over 40 countries distribution. The company also has a subsidiary, HemexDx, operating in India supporting local manufacturing and commercial operations.
Differentiator
Problem solved
Functional benefit
Brands
- Gazelle: Point-of-care diagnostic platform that detects and quantifies blood-based conditions including sickle cell disease, beta thalassemia, and iron-related disorders. Uses miniaturized electrophoresis and fluorescent immunoassay technologies.
Products and services
- Gazelle Hb Variant Test Point-of-care diagnostic test using microchip electrophoresis to detect and quantify hemoglobin variants (HbS, HbA, HbF, HbA2, HbC/E) for diagnosing sickle cell disease and beta thalassemia. Delivers quantitative results in 8 minutes from a small whole blood sample, suitable for use by frontline healthcare workers in low-resource settings.
- Gazelle Ferritin FIA Test Portable, battery-powered whole blood ferritin test using fluorescent immunoassay (FIA) technology for detecting iron deficiency anemia. Test strip development takes 15 minutes with results displayed onscreen in 20 seconds, using proprietary AI-guided imaging for improved sensitivity and quantification.
- Gazelle Diagnostic Platform Core diagnostic platform combining microchip electrophoresis and fluorescent immunoassay technologies with AI-driven algorithms. Supports point-of-care testing for hemoglobin disorders and anemia, delivers results in 8 minutes, and provides digital report storage and transmission capabilities.
- Gazelle Reader Portable diagnostic device that reads Gazelle test strips, displays results on a color touchscreen, and stores digital patient reports. Supports automatic over-the-air software updates and data transfer via USB, printer, or cloud connection. Designed for low-resource and challenging environments.
- Gazelle Cloud Application Cloud-based application enabling upload of patient reports from Gazelle Readers, web-based access for authorized users, PDF report generation, device status dashboard, and APIs for third-party EMR and LIS integration.
- Gazelle S10B Multipack Multi-test pack (consumable) for the Gazelle Hb Variant Test, sold through Hemex Health's distributor network for use with the Gazelle Reader.
Quantifiable outcome
- 100% sensitivity for identifying homozygous sickle cell disease; 98.4% sensitivity for sickle cell trait in Indian study of 470 patients
- +3 more outcomes
Companies that use Hemex Health
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Hemex Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability3 records
Feature5 records
Hemex Health partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- CureleadscorePartnership to commercialize AI-based Gazelle diagnostic device across Middle East, Turkey, and North Africa. Cureleads serves as the exclusive distributor for UAE.
- Novartis BiomeminorCollaboration with Novartis Biome to bring diagnostics and therapeutics to Sub-Saharan Africa. CEO Patti White and Robin Roberts of Novartis Biome discussed the collaboration.
- Syrma Johari MedtechcoreStrategic partnership mentioned in 360Dx article as part of Hemex's transition from startup to scale-up. Suhas Tamras, CEO of Syrma Johari Medtech, serves on the HemexDx Board of Directors.
- Case Western Reserve UniversitycoreResearch collaboration with leading Indian researchers and institutions. Dr. Umut Gurkan, inventor of microchip electrophoresis technology, leads the Case Biomanufacturing and Microfabrication Laboratory and serves as Chief Scientist and advisor to Hemex Health.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Hemex Health competitors and assessment
Company assessmentDirect peers
- Tosoh Bioscience: Tosoh markets HPLC analyzers (HLC-723 G8/G11) widely used for HbA1c and hemoglobin variant testing. It competes with Hemex in the hemoglobin variant testing category, particularly in central laboratory settings.
- Bio-Rad Laboratories: Bio-Rad's Variant II HPLC system is the dominant reference-standard for hemoglobin variant identification and quantification in clinical labs. Hemex's Gazelle competes against this gold standard by offering a decentralized, POC alternative with comparable accuracy.
- Trinity Biotech: Trinity Biotech markets the Premier Hb9210 and other hemoglobin electrophoresis / HPLC products for diagnosing hemoglobinopathies. It is one of the closest direct competitors to Gazelle in the sickle cell and beta thalassemia diagnostic category.
- Sebia: Sebia is a global leader in capillary electrophoresis for hemoglobin variant separation and quantification (MINICAP, CAPILLARYS systems). Sebia's hemoglobinopathy franchise directly competes with Hemex's microchip electrophoresis-based approach.
- Helena Laboratories: Helena manufactures hemoglobin electrophoresis systems and related supplies used in clinical labs for sickle cell and thalassemia screening. It is a relevant direct comparator in the hemoglobinopathy diagnostic space.
- HemoCue (Danaher): HemoCue is a pioneer in point-of-care hemoglobin testing (Hb and HbA1c analyzers). Hemex's Gazelle Ferritin FIA test and broader POC hemoglobin franchise share HemoCue's point-of-care philosophy and target users in primary care and low-resource settings.
- EKF Diagnostics: EKF Diagnostics manufactures point-of-care hemoglobin, HbA1c, and related hematology analyzers (Hemo Control, QuikRead). EKF and Hemex both target decentralized POC hematology markets including emerging economies.
Broad incumbents
- Abbott Diagnostics: Abbott Diagnostics operates one of the broadest POC and central-lab diagnostic portfolios (i-STAT, Afinion, CELL-DYN). Hemex's VP of Business Development previously worked at Abbott, and Abbott is a broad incumbent that could enter or expand in POC hemoglobin variant testing.
- Siemens Healthineers: Siemens Healthineers offers the ADVIA Centaur and Atellica systems for clinical chemistry and hematology diagnostics. While its focus is broader than hemoglobinopathy-specific testing, it is a large incumbent shaping the diagnostic infrastructure Hemex complements in low-resource settings.
- Sysmex: Sysmex is a global leader in hematology analyzers (XN-series) and increasingly in clinical chemistry. Sysmex is a broad incumbent in the central hematology diagnostics market that Hemex's Gazelle platform could complement or, over time, face competition from in POC form factors.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Hemex Health social profiles
Digital presenceHemex Health compliance and trust
Trust signalCompliance1 record
Hemex Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hemex Health leadership team
Management profileNumber of profiles
Profiles8 records
Hemex Health subsidiaries and ownership
Company hierarchySubsidiaries1 record
Hemex Health funding detail
Funding detailFunding overview
Funding rounds9 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hemex Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hemex Health
What does Hemex Health do?
Hemex Health develops and sells the Gazelle diagnostic platform, a point-of-care system combining a portable reader device with proprietary microchip electrophoresis and fluorescent immunoassay (FIA) test cartridges to detect and quantify hemoglobin variants (sickle cell disease, beta thalassemia) and ferritin (iron deficiency anemia) in 8 minutes from a small whole blood sample, supported by AI-driven result interpretation and a cloud application for data management.
Is Hemex Health a public or private company?
Hemex Health is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hemex Health founded?
Hemex Health was founded in 2016. It employs 1 to 10 people.
Where is Hemex Health based?
Hemex Health is headquartered in Portland, United States, in the North America region.
How does Hemex Health make money?
Three revenue lines are on record. Gazelle Diagnostic Device (Reader) is the primary driver. The others are gazelle Hb Variant Test Multipacks and gazelle Ferritin FIA Test Strips.
Who are Hemex Health's main competitors?
Direct peers on record are Tosoh Bioscience, Bio-Rad Laboratories, Trinity Biotech, Sebia, Helena Laboratories, HemoCue (Danaher) and EKF Diagnostics. Broad incumbents are Abbott Diagnostics, Siemens Healthineers and Sysmex.
Does Hemex Health have an API?
Yes. Gazelle Cloud Application provides Application Programming Interfaces (APIs) to allow third-party software development for electronic medical records systems (EMRs) to access Hemex Cloud data. The platform also supports data transfer to LIS systems via USB, with results downloadable to personal computers or transferable to cloud storage.
What industry is Hemex Health in?
Hemex Health's product category is In-vitro diagnostic medical devices. Its primary akta.pro industry code is HLAHAOAD, Hematology POCT (CBC/hemoglobin/hematocrit), with a secondary code of HLAHAAAB, Hematology & Coagulation Diagnostics. Its NAICS code is 334516 and its SIC code is 3826.